Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 2/2019

01-02-2019 | Brief Report

Baicalein and baicalin as Zika virus inhibitors

Authors: Adrian Oo, Boon Teong Teoh, Sing Sin Sam, Sazaly Abu Bakar, Keivan Zandi

Published in: Archives of Virology | Issue 2/2019

Login to get access

Abstract

At present, there is no effective antiviral agent for Zika virus (ZIKV), an arbovirus that is known for its teratogenic effects on newborns. Baicalein and baicalin were found to be capable of downregulating ZIKV replication up to 10 hours postinfection, while prophylactic effects were evident in pre-treated cells. Baicalein exhibited its highest potency during intracellular ZIKV replication, whereas baicalin was most effective against virus entry. Our in silico interaction assays predicted that both compounds exhibited the strongest binding affinities towards ZIKV NS5, while the virus envelope glycoprotein was the least likely target protein. These findings serve as a crucial platform for further in-depth studies to decipher the underlying anti-ZIKV mechanism(s) of each compound.
Literature
1.
Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D (2017) An update on Zika virus infection. The Lancet 390:2099–2109
2.
Heukelbach J, Alencar CH, Kelvin AA, de Oliveira WK, de Góes Cavalcanti LP (2016) Zika virus outbreak in Brazil. J Infect Dev Ctries 10(02):116–120CrossRefPubMed
3.
Méndez N, Oviedo-Pastrana M, Mattar S, Caicedo-Castro I, Arrieta G (2017) Zika virus disease, microcephaly and Guillain-Barré syndrome in Colombia: epidemiological situation during 21 months of the Zika virus outbreak, 2015–2017. Arch Public Health 75(1):65CrossRefPubMedPubMedCentral
4.
Chang C, Ortiz K, Ansari A, Gershwin ME (2016) The Zika outbreak of the 21st century. J Autoimmun 68:1–13CrossRefPubMed
5.
Holtzman M, Golden WC, Sheffield JS (2018) Zika virus infection in the pregnant woman. Clin Obstet Gynecol 61(1):177–185PubMed
6.
de Souza AS, de Oliveira-Szjenfeld PS, de Oliveira Melo AS, de Souza LAM, Batista AGM, Tovar-Moll F (2018) Imaging findings in congenital Zika virus infection syndrome: an update. Child Nerv Syst 34(1):85–93CrossRef
7.
Gaudry A, Bos S, Viranaicken W, Roche M, Krejbich-Trotot P, Gadea G, Desprès P, El-Kalamouni C (2018) The flavonoid isoquercitrin precludes initiation of Zika virus infection in human cells. Int J Mol Sci 19(4):1093CrossRefPubMedCentral
8.
Mounce BC, Cesaro T, Carrau L, Vallet T, Vignuzzi M (2017) Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding. Antivir Res 142:148–157CrossRefPubMed
9.
Carneiro BM, Batista MN, Braga ACS, Nogueira ML, Rahal P (2016) The green tea molecule EGCG inhibits Zika virus entry. Virology 496:215–218CrossRefPubMed
10.
Zandi K, Teoh B-T, Sam S-S, Wong P-F, Mustafa MR, AbuBakar S (2012) Novel antiviral activity of baicalein against dengue virus. BMC Complement Altern Med 12(1):214CrossRefPubMedPubMedCentral
11.
Moghaddam E, Teoh B-T, Sam S-S, Lani R, Hassandarvish P, Chik Z, Yueh A, Abubakar S, Zandi K (2014) Baicalin, a metabolite of baicalein with antiviral activity against dengue virus. Sci Rep 4:5452CrossRefPubMedPubMedCentral
12.
Oo A, Rausalu K, Merits A, Higgs S, Vanlandingham D, Bakar SA, Zandi K (2018) Deciphering the potential of baicalin as an antiviral agent for Chikungunya virus infection. Antivir Res 150:101–111CrossRefPubMed
13.
Jin J, Chen Y, Wang D, Ma L, Guo M, Zhou C, Dou J (2018) The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity. Arch Pharm Res 41(6):664–676CrossRefPubMed
14.
15.
Hassandarvish P, Rothan HA, Rezaei S, Yusof R, Abubakar S, Zandi K (2016) In silico study on baicalein and baicalin as inhibitors of dengue virus replication. RSC Adv 6(37):31235–31247CrossRef
16.
Bullard-Feibelman KM, Govero J, Zhu Z, Salazar V, Veselinovic M, Diamond MS, Geiss BJ (2017) The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antivir Res 137:134–140CrossRefPubMed
17.
Chan JF-W, Chik KK-H, Yuan S, Yip CC-Y, Zhu Z, Tee K-M, Tsang JO-L, Chan CC-S, Poon VK-M, Lu G (2017) Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor. Antivir Res 141:29–37CrossRefPubMed
18.
Johari J, Kianmehr A, Mustafa MR, Abubakar S, Zandi K (2012) Antiviral activity of baicalein and quercetin against the Japanese encephalitis virus. Int J Mol Sci 13(12):16785–16795CrossRefPubMedPubMedCentral
19.
Li BQ, Fu T, Dongyan Y, Mikovits JA, Ruscetti FW, Wang JM (2000) Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry. Biochem Biophys Res Commun 276(2):534–538CrossRefPubMed
20.
Cheng F, da Silva SR, Huang I-C, Jung JU, Gao S-J (2018) Suppression of Zika virus infection and replication in endothelial cells and astrocytes by PKA inhibitor PKI 14-22. J Virol 92(4):e02019–02017
21.
Fink SL, Vojtech L, Wagoner J, Slivinski NS, Jackson KJ, Wang R, Khadka S, Luthra P, Basler CF, Polyak SJ (2018) The antiviral drug arbidol inhibits Zika virus. Sci Rep 8(1):8989CrossRefPubMedPubMedCentral
22.
Wang B, Thurmond S, Hai R, Song J (2018) Structure and function of Zika virus NS5 protein: perspectives for drug design. Cell Mol Life Sci 75(10):1723–1736CrossRefPubMedPubMedCentral
23.
Sacramento CQ, De Melo GR, De Freitas CS, Rocha N, Hoelz LVB, Miranda M, Fintelman-Rodrigues N, Marttorelli A, Ferreira AC, Barbosa-Lima G (2017) The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci Rep 7:40920CrossRefPubMedPubMedCentral
24.
Goo L, DeMaso CR, Pelc RS, Ledgerwood JE, Graham BS, Kuhn RJ, Pierson TC (2018) The Zika virus envelope protein glycan loop regulates virion antigenicity. Virology 515:191–202CrossRefPubMed
25.
Persaud M, Martinez-Lopez A, Buffone C, Porcelli SA, Diaz-Griffero F (2018) Infection by Zika viruses requires the transmembrane protein AXL, endocytosis and low pH. Virology 518:301–312CrossRefPubMed
26.
Meertens L, Labeau A, Dejarnac O, Cipriani S, Sinigaglia L, Bonnet-Madin L, Le Charpentier T, Hafirassou ML, Zamborlini A, Cao-Lormeau V-M (2017) Axl mediates ZIKA virus entry in human glial cells and modulates innate immune responses. Cell Rep 18(2):324–333CrossRefPubMed
27.
Chu M, Xu L, Zhang M-b, Chu Z-y, Wang Y-d (2015) Role of Baicalin in anti-influenza virus A as a potent inducer of IFN-gamma. BioMed research international 2015
28.
Li M, Shi A, Pang H, Xue W, Li Y, Cao G, Yan B, Dong F, Li K, Xiao W (2014) Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects. J Ethnopharmacol 156:210–215CrossRefPubMed
29.
Fangueiro JF, Calpena AC, Clares B, Andreani T, Egea MA, Veiga FJ, Garcia ML, Silva AM, Souto EB (2016) Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs): in vivo, in vitro and ex vivo studies. Int J Pharm 502(1–2):161–169CrossRefPubMed
30.
Pechenov S, Bhattacharjee H, Yin D, Mittal S, Subramony JA (2017) Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery. Adv Drug Deliv Rev 112:106–122CrossRefPubMed
31.
Liu J, Lv S-S, Fu Z-Y, Hou L-L (2018) Baicalein enhances migration and invasion of extravillous trophoblasts via activation of the NF-κB pathway. Med Sci Monit 24:2983CrossRefPubMedPubMedCentral
32.
Wang G, Liang J, L-r Gao, Z-p Si, X-t Zhang, Liang G, Yan Y, Li K, Cheng X, Bao Y (2018) Baicalin administration attenuates hyperglycemia-induced malformation of cardiovascular system. Cell Death Dis 9(2):234CrossRefPubMedPubMedCentral
Metadata
Title
Baicalein and baicalin as Zika virus inhibitors
Authors
Adrian Oo
Boon Teong Teoh
Sing Sin Sam
Sazaly Abu Bakar
Keivan Zandi
Publication date
01-02-2019
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 2/2019
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-018-4083-4

Other articles of this Issue 2/2019

Archives of Virology 2/2019 Go to the issue

Annotated Sequence Record

Characterization of the L genome segment of an orthohantavirus isolated from Niviventer confucianus

Original Article

Molecular characterization and phylogenetic analysis of very virulent infectious bursal disease virus circulating in Morocco during 2016-2017

Original Article

Development and application of high-resolution melting analysis for the classification of infectious laryngotracheitis virus strains and detection of recombinant progeny

Brief Report

Phytophthora infestans RNA virus 2, a novel RNA virus from Phytophthora infestans, does not belong to any known virus group

Annotated Sequence Record

Bovine papillomavirus 24: a novel member of the genus Xipapillomavirus detected in the Amazon region

Original Article

Analysis of fitness differences of hepatitis B virus genotypes D and F using a cotransfection assay
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits